TY - JOUR
T1 - Health related quality of life following open versus minimally invasive total gastrectomy for cancer: Results from a randomized clinical trial
AU - van der Wielen, Nicole
AU - Daams, Freek
AU - Rosati, Riccardo
AU - Parise, Paolo
AU - Weitz, J. rgen
AU - Reissfelder, Christoph
AU - Diez del Val, Ismael
AU - Loureiro, Carlos
AU - Parada-González, Purificación
AU - Pintos-Martínez, Elena
AU - Vallejo, Francisco Mateo
AU - Achirica, Carlos Medina
AU - Sánchez-Pernaute, Andrés
AU - Campos, Adriana Ruano
AU - Bonavina, Luigi
AU - Asti, Emanuele L. G.
AU - Poza, Alfredo Alonso
AU - Gilsanz, Carlos
AU - Nilsson, Magnus
AU - Lindblad, Mats
AU - Gisbertz, Suzanne S.
AU - van Berge Henegouwen, Mark I.
AU - Romario, Uberto Fumagalli
AU - de Pascale, Stefano
AU - Akhtar, Khurshid
AU - Bonjer, H. Jaap
AU - Cuesta, Miguel A.
AU - van der Peet, Donald L.
AU - Straatman, Jennifer
N1 - Funding Information: The STOMACH trial received funding by Fonds NutsOhra (FNO) . This was given to the department of gastro-intestinal surgery at Amsterdam University Medical Center, location VU university. All other authors declare no conflict of interest. Funding Information: The STOMACH trial received funding by Fonds NutsOhra (FNO). This was given to the department of gastro-intestinal surgery at Amsterdam University Medical Center, location VU university. All other authors declare no conflict of interest. Publisher Copyright: © 2021 The Authors
PY - 2022/3
Y1 - 2022/3
N2 - Introduction: Minimally invasive techniques show improved short-term and comparable long-term outcomes compared to open techniques in the treatment of gastric cancer and improved survival has been seen with the implementation of multimodality treatment. Therefore, focus of research has shifted towards optimizing treatment regimens and improving quality of life. Materials and methods: A randomized trial was performed in thirteen hospitals in Europe. Patients were randomized between open total gastrectomy (OTG) or minimally invasive total gastrectomy (MITG) after neoadjuvant chemotherapy. This study investigated patient reported outcome measures (PROMs) on health-related quality of life (HRQoL) following OTG or MITG, using the Euro-Qol-5D (EQ-5D) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires, modules C30 and STO22. Due to multiple testing a p-value < 0.001 was deemed statistically significant. Results: Between January 2015 and June 2018, 96 patients were included in this trial. Forty-nine patients were randomized to OTG and 47 to MITG. A response compliance of 80% was achieved for all PROMs. The EQ5D overall health score one year after surgery was 85 (60–90) in the open group and 68 (50–83.8) in the minimally invasive group (P = 0.049). The median EORTC-QLQ-C30 overall health score one year postoperatively was 83,3 (66,7–83,3) in the open group and 58,3 (35,4–66,7) in the minimally invasive group (P = 0.002). This was not statistically significant. Conclusion: No differences were observed between open total gastrectomy and minimally invasive total gastrectomy regarding HRQoL data, collected using the EQ-5D, EORTC QLQ-C30 and EORTC-QLQ-STO22 questionnaires.
AB - Introduction: Minimally invasive techniques show improved short-term and comparable long-term outcomes compared to open techniques in the treatment of gastric cancer and improved survival has been seen with the implementation of multimodality treatment. Therefore, focus of research has shifted towards optimizing treatment regimens and improving quality of life. Materials and methods: A randomized trial was performed in thirteen hospitals in Europe. Patients were randomized between open total gastrectomy (OTG) or minimally invasive total gastrectomy (MITG) after neoadjuvant chemotherapy. This study investigated patient reported outcome measures (PROMs) on health-related quality of life (HRQoL) following OTG or MITG, using the Euro-Qol-5D (EQ-5D) and the European Organization for Research and Treatment of Cancer (EORTC) questionnaires, modules C30 and STO22. Due to multiple testing a p-value < 0.001 was deemed statistically significant. Results: Between January 2015 and June 2018, 96 patients were included in this trial. Forty-nine patients were randomized to OTG and 47 to MITG. A response compliance of 80% was achieved for all PROMs. The EQ5D overall health score one year after surgery was 85 (60–90) in the open group and 68 (50–83.8) in the minimally invasive group (P = 0.049). The median EORTC-QLQ-C30 overall health score one year postoperatively was 83,3 (66,7–83,3) in the open group and 58,3 (35,4–66,7) in the minimally invasive group (P = 0.002). This was not statistically significant. Conclusion: No differences were observed between open total gastrectomy and minimally invasive total gastrectomy regarding HRQoL data, collected using the EQ-5D, EORTC QLQ-C30 and EORTC-QLQ-STO22 questionnaires.
KW - Gastric cancer
KW - Minimally invasive gastrectomy
KW - Open gastrectomy
KW - Quality of life
UR - http://www.scopus.com/inward/record.url?scp=85114423513&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.ejso.2021.08.031
DO - https://doi.org/10.1016/j.ejso.2021.08.031
M3 - Article
C2 - 34503850
SN - 0748-7983
VL - 48
SP - 553
EP - 560
JO - European Journal of Surgical Oncology
JF - European Journal of Surgical Oncology
IS - 3
ER -